| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 214.66% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 10/11/2023 | 214.66% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 09/06/2023 | 214.66% | HC Wainwright & Co. | $9 → $4 | Maintains | Buy |
| 08/10/2023 | 607.99% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 07/24/2023 | 607.99% | HC Wainwright & Co. | $9 → $9 | Reiterates | Buy → Buy |
| 06/21/2023 | 607.99% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/11/2023 | 607.99% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 03/30/2023 | 607.99% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 11/11/2022 | — | Dawson James | Downgrades | Buy → Neutral | |
| 12/20/2021 | 607.99% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 04/16/2021 | — | Dawson James | Downgrades | Buy → Neutral | |
| 09/21/2020 | 804.66% | Alliance Global Partners | → $11.5 | Initiates Coverage On | → Buy |
| 11/26/2019 | 1630.65% | Brookline Capital | → $22 | Initiates Coverage On | → Buy |
| 10/10/2019 | 607.99% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
What is the target price for BioCardia (BCDA)?
The latest price target for BioCardia (NASDAQ: BCDA) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $4.00 expecting BCDA to rise to within 12 months (a possible 214.66% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioCardia (BCDA)?
The latest analyst rating for BioCardia (NASDAQ: BCDA) was provided by HC Wainwright & Co., and BioCardia reiterated their buy rating.
When is the next analyst rating going to be posted or updated for BioCardia (BCDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCardia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCardia was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating BioCardia (BCDA) correct?
While ratings are subjective and will change, the latest BioCardia (BCDA) rating was a reiterated with a price target of $0.00 to $4.00. The current price BioCardia (BCDA) is trading at is $1.27, which is within the analyst's predicted range.